NO20055943L - Bicalutamidformer, sammensetninger og fremgangsmater derav - Google Patents

Bicalutamidformer, sammensetninger og fremgangsmater derav

Info

Publication number
NO20055943L
NO20055943L NO20055943A NO20055943A NO20055943L NO 20055943 L NO20055943 L NO 20055943L NO 20055943 A NO20055943 A NO 20055943A NO 20055943 A NO20055943 A NO 20055943A NO 20055943 L NO20055943 L NO 20055943L
Authority
NO
Norway
Prior art keywords
bicalutamide
compositions
methods
forms
composition
Prior art date
Application number
NO20055943A
Other languages
English (en)
Norwegian (no)
Inventor
Arturo Siles Ortega
Joan Cucala Escoi
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of NO20055943L publication Critical patent/NO20055943L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055943A 2003-05-14 2005-12-14 Bicalutamidformer, sammensetninger og fremgangsmater derav NO20055943L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47022403P 2003-05-14 2003-05-14
PCT/EP2004/005189 WO2004100944A1 (en) 2003-05-14 2004-05-13 Bicalutamide forms, compositions, and processes thereof

Publications (1)

Publication Number Publication Date
NO20055943L true NO20055943L (no) 2006-01-25

Family

ID=33452382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055943A NO20055943L (no) 2003-05-14 2005-12-14 Bicalutamidformer, sammensetninger og fremgangsmater derav

Country Status (9)

Country Link
US (1) US20050008691A1 (enExample)
EP (1) EP1622604A1 (enExample)
JP (1) JP2006528221A (enExample)
AU (1) AU2004238038A1 (enExample)
CA (1) CA2525318A1 (enExample)
FI (1) FI7526U1 (enExample)
NO (1) NO20055943L (enExample)
WO (1) WO2004100944A1 (enExample)
ZA (1) ZA200509152B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms
ES2368838T3 (es) * 2004-07-14 2011-11-22 Sumitomo Chemical Company Limited Procedimiento para la cristalización de la bicalutamida.
WO2006103689A1 (en) * 2005-03-29 2006-10-05 Usv Limited Process for preparation of bicalutamide
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014864A1 (en) * 2005-07-15 2007-01-18 Teva Pharmaceutical Industries, Ltd. Novel pharmaceutical granulate
CN101222911A (zh) * 2005-07-15 2008-07-16 特瓦制药工业有限公司 新的制粒方法及由此制备的颗粒
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CZ299577B6 (cs) * 2005-12-20 2008-09-03 Interpharma Praha, A. S. Zpusob výroby vysoce cistého 4-kyano-3-trifluoromethyl-N-(3-p-fluorfenylsulfonyl-2-hydroxy-2-methylpropionyl) anilinu
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
UA92233C2 (ru) * 2006-07-07 2010-10-11 Панасэа Биотэк Лимитэд Способы и композиции для получения антиандрогенного эффекта
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
PL2063861T3 (pl) * 2006-09-15 2015-07-31 Echo Pharmaceuticals Bv Jednostka dawkowania do podawania podjęzykowego, podpoliczkowego lub doustnego nierozpuszczalnych w wodzie substancji aktywnych farmaceutycznie
JP2010503663A (ja) * 2006-09-15 2010-02-04 エコ・ファーマシューティカルズ・ビー．ブイ． 医薬活性物質を含む顆粒剤とその製造方法
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
GB0702826D0 (en) * 2007-02-14 2007-03-28 Pliva Istrazivanje I Razvoj D Preparation and composition of solid dosage form containing Bicalutamide
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CN102238941A (zh) * 2008-09-17 2011-11-09 迈兰实验室公司 颗粒、制备它们的方法和包含它们的药物产品
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3060316A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
WO1998055153A1 (en) * 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
HU223950B1 (hu) 1999-06-10 2005-03-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás a racém, valamint az R-(-)- és S-(+)-N-[4-ciano-3-(trifluor-metil)-fenil]-3-[(4-fluor-fenil)-szulfonil]-2-hidroxi-2-metil-propánsavamid előállítására
NZ527532A (en) * 2001-02-27 2004-12-24 Astrazeneca Ab Pharmaceutical formulation comprising bicalutamide
HUP0303454A3 (en) * 2001-04-02 2005-12-28 Astrazeneca Ab Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
US6458769B1 (en) * 2001-06-25 2002-10-01 Astrazeneca Ab Amorphous compound
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040063782A1 (en) * 2002-09-27 2004-04-01 Westheim Raymond J.H. Bicalutamide forms

Also Published As

Publication number Publication date
FI7526U1 (fi) 2007-06-12
EP1622604A1 (en) 2006-02-08
JP2006528221A (ja) 2006-12-14
US20050008691A1 (en) 2005-01-13
AU2004238038A1 (en) 2004-11-25
ZA200509152B (en) 2007-04-25
FIU20060440U0 (fi) 2006-10-25
CA2525318A1 (en) 2004-11-25
WO2004100944A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
NO20055943L (no) Bicalutamidformer, sammensetninger og fremgangsmater derav
TW200626142A (en) Chemical compounds
UA84208C2 (en) Tetraazabenzo(e)azulene derivatives and analogs thereof
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
WO2003064387A3 (en) Substituted indoles as alpha-1 agonists
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
EA200601868A1 (ru) 3- или 4-монозамещённые производные фенола и тиофенола, полезные в качестве н-лигандов
ATE495747T1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
BRPI0408631A (pt) composição protéica em pó
MY135954A (en) Crystalline form of (s)-ethoxy-3-4-(2-4-methanesulfonyloxyphenyl ethoxy) phenyl] propanoic acid
BRPI0519414A2 (pt) composiÇço oral, composiÇço em pasta ou gel, e, mÉtodos para inibir crescimento bacteriano na cavidade oral, e para manter saéde sistÊmica
TW200610758A (en) Alpha crystalline form of strontium ranelate, a process for its preparation, and pharmaceutical compositions containing it
NO20054787L (no) Indenderivater som farmasotiske midler
IL178122A0 (en) Materials and methods for treating coagulation disorders
WO2008078453A1 (ja) 血小板産生促進因子及びその利用
TW200738588A (en) Chemical compounds
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
EP1694645A4 (en) AMLODIPINE GENTISATE AND METHOD OF MANUFACTURE
MXPA05013161A (es) Analogos de colchicosido.
NO20092413L (no) Pyrazolanaloger
TNSN05291A1 (en) Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
WO2007000655A3 (en) Novel pyrazolopyrimidinone derivatives
GB2415377A (en) Hepatoprotective pharmaceutical composition comprising a mixture of coumarinolignoids and process for preparation thereof
RU2003125376A (ru) Композиции, содержащие циклогексамантан
Gligor et al. ASSESSMENT OF THE EFFECTS OF IBUPROFEN ASSOCIATION WITH NIFEDIPINE ON IBUPROFEN INDUCED HEPATOTOXICITY

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application